| Name | Title | Contact Details |
|---|
biomarkerinc is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east
Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator. Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with the global biopharmaceutical companies by providing a financing solution to them as sponsors of clinical trials, which are conducted by patient care providers (PCPs) such as hospitals, medical research institutes, centers, and clinics.
22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.
InnovaPrep is engaged in product development, manufacturing, sales, service, and related out-licensing of a collection of novel technologies enabling rapid detection of biological particles and pathogens. Our core business is biological sample collection, concentration and preparation. The company has commercialized a collection of market-disruptive platform technologies for rapid, automated concentration of biological particles. InnovaPrep`s 35 pending and awarded patents apply to highly efficient collection, recovery, and concentration of biological particles from air, surfaces, and liquids. Our elution process underlies many of these patents and enables recovery of particles from filters, membranes, surfaces, and objects. The primary utility for these technologies is to greatly improve the way biological samples, especially those containing pathogenic organisms, are collected and prepared for analysis beyond the state-of-the-art. These technologies fill a critical void that currently severely limits application of the most advanced biological detection systems to the billions of microbiological tests performed annually. Markets served: Biodefense, food safety, water safety, biopharma, clinical research, animal health, environmental monitoring and others.